DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 144 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 0.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $271,585 | -7.8% | 21,351 | +2.0% | 0.00% | – |
Q2 2023 | $294,666 | +1.8% | 20,928 | +11.7% | 0.00% | – |
Q1 2023 | $289,440 | +2.0% | 18,734 | +8.3% | 0.00% | – |
Q4 2022 | $283,629 | -11.4% | 17,305 | 0.0% | 0.00% | – |
Q3 2022 | $320,143 | +40.4% | 17,305 | 0.0% | 0.00% | -100.0% |
Q2 2022 | $228,000 | +51.0% | 17,305 | +5.7% | 0.00% | – |
Q1 2022 | $151,000 | +7.1% | 16,365 | +13.4% | 0.00% | – |
Q4 2021 | $141,000 | -79.4% | 14,431 | -28.3% | 0.00% | -100.0% |
Q3 2021 | $685,000 | -6.5% | 20,139 | +0.6% | 0.00% | 0.0% |
Q2 2021 | $733,000 | -19.4% | 20,020 | -1.2% | 0.00% | -50.0% |
Q1 2021 | $909,000 | -15.0% | 20,262 | +8.1% | 0.00% | 0.0% |
Q4 2020 | $1,069,000 | +40.3% | 18,737 | +26.1% | 0.00% | 0.0% |
Q3 2020 | $762,000 | -1.3% | 14,858 | +15.0% | 0.00% | 0.0% |
Q2 2020 | $772,000 | +82.1% | 12,920 | +25.5% | 0.00% | +100.0% |
Q1 2020 | $424,000 | -29.2% | 10,298 | +7.0% | 0.00% | 0.0% |
Q4 2019 | $599,000 | +154.9% | 9,626 | +39.0% | 0.00% | 0.0% |
Q3 2019 | $235,000 | – | 6,923 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
New Leaf Venture Partners, L.L.C. | 2,086,723 | $85,910,000 | 25.70% |
SV Health Investors, LLC | 449,951 | $18,525,000 | 15.54% |
Redmile Group, LLC | 5,116,263 | $210,637,000 | 5.90% |
Eversept Partners, LP | 414,081 | $17,047,715 | 4.24% |
Sunesis Advisors, LLC | 96,299 | $3,965,000 | 3.99% |
Avoro Capital Advisors LLC | 2,000,000 | $82,340,000 | 2.78% |
Opaleye Management Inc. | 222,000 | $9,140,000 | 2.42% |
SECTORAL ASSET MANAGEMENT INC | 204,059 | $8,401,000 | 1.61% |
Artal Group S.A. | 800,000 | $32,936,000 | 1.39% |
Atika Capital Management LLC | 141,000 | $5,805,000 | 1.11% |